Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome

Younger patients with COVID-19 may experience an exaggerated immune response to SARS-CoV-2 infection and develop cytokine release syndrome (CRS), which may be life threatening. There is no proven antiviral therapy for COVID-19 so far, but profound immunosuppression has recently been suggested as a t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Case Rep Intern Med
Autores principales: van Kraaij, Tom DA, Mostard, Rémy LM, Ramiro, Sofia, Magro Checa, Cesar, van Dongen, Christel MP, van Haren, Eric HJ, Buijs, Jacqueline, Landewé, Robert BM
Formato: Artigo
Lenguaje:Inglês
Publicado: SMC Media Srl 2020
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7213824/
https://ncbi.nlm.nih.gov/pubmed/32399455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12890/2020_001675
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares